Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) is a clinical-stage immunology-based biopharmaceutical company, and its news flow reflects the progress and risks of drug development in inflammatory and immunological diseases. Company announcements routinely describe advances in its pipeline, particularly its anti-IgE monoclonal antibody program ozureprubart (formerly RPT904), as well as financial updates and investor outreach activities.
Visitors to this news page can review press releases on key clinical milestones, such as FDA clearance of an Investigational New Drug application, initiation of the prestIgE Phase 2b trial of ozureprubart in IgE-mediated food allergy, and positive topline data from a Phase 2 trial in chronic spontaneous urticaria conducted by partner Shanghai Jeyou Pharmaceutical Co., Ltd. RAPT’s news also highlights how these data compare to existing therapies like omalizumab in terms of dosing intervals and measured endpoints within the reported studies.
RAPT frequently reports quarterly financial results, detailing research and development and general and administrative expenses, net losses and cash, cash equivalents and marketable securities. News items also cover capital-raising events, such as the pricing and completion of underwritten public offerings of common stock, and the company’s estimates regarding how long its capital resources may fund operations based on current plans.
In addition, RAPT issues press releases about participation in healthcare and investor conferences, including major events hosted by firms such as J.P. Morgan, Wells Fargo, Guggenheim, Stifel, TD Cowen, Cantor and H.C. Wainwright. These updates indicate when management will present company overviews or fireside chats and how investors can access related webcasts or archived presentations.
For investors and observers following RAPT, this news feed provides a consolidated view of clinical trial developments, regulatory interactions, financial disclosures and corporate events that shape the company’s progress in developing therapies for inflammatory and immunological diseases.
RAPT Therapeutics announced positive topline results from its Phase 1b clinical trial of RPT193 for moderate-to-severe atopic dermatitis, presented at the EADV Congress. The trial demonstrated significant efficacy across key exploratory endpoints including EASI and vIGA, with benefits observed persisting two weeks post-treatment. RPT193 was well tolerated, showing a clean safety profile with no serious adverse events. The company plans to advance RPT193 to a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma, highlighting its potential in treating inflammatory diseases.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Brian Wong will present at the 2021 Cantor Virtual Healthcare Conference on September 27, 2021, at 2:00 p.m. EST. The company focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases, with two drug candidates, FLX475 and RPT193, targeting CCR4 receptors. For access to the live webcast and archived recordings, visit the RAPT Therapeutics website.
RAPT Therapeutics announced it will present clinical safety and efficacy data for RPT193, an oral CCR4 inhibitor, from its Phase 1b trial targeting moderate-to-severe atopic dermatitis at the upcoming 30th European Academy of Dermatology and Venereology Congress on September 30, 2021. The presentation highlights a significant step in RAPT's ongoing commitment to develop novel therapies for unmet needs in oncology and inflammatory diseases.
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2021 – RAPT Therapeutics (Nasdaq: RAPT) announced that Brian Wong, M.D., Ph.D., President and CEO, will present at key investor conferences in September. Notably, he will speak at the Wells Fargo 2021 Virtual Healthcare Conference on September 9 at 8:00 a.m. EST and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. EST. For live webcasts and archived recordings, visit RAPT's official website. RAPT focuses on oral therapies for oncology and inflammatory diseases, advancing drug candidates targeting CCR4.
RAPT Therapeutics reported Q2 2021 financial results, highlighting a net loss of $16.1 million, up from $12.4 million year-over-year. R&D expenses rose to $13.2 million, driven by clinical trial costs for FLX475. The company successfully completed a public offering, generating $134.6 million, enhancing its cash position to $223.3 million. Notable achievements include positive topline results from the Phase 1b trial of RPT193 for atopic dermatitis. RAPT remains optimistic about advancing its drug development initiatives in oncology and inflammatory diseases.
RAPT Therapeutics has successfully closed its underwritten public offering of 4,356,060 shares of common stock at $33.00 per share, raising approximately $143.7 million before expenses. This includes 568,181 shares sold due to underwriters' full exercise of their option. The offering was made under an effective shelf registration statement filed with the SEC. J.P. Morgan, SVB Leerink, and Piper Sandler acted as joint lead book-running managers for this offering.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced a public offering of 3,787,879 shares at $33.00 each, aiming for approximately $125 million in gross proceeds. The offering, set to close on June 18, 2021, is managed by J.P. Morgan, SVB Leerink, and Piper Sandler. A 30-day option for underwriters to purchase an additional 568,181 shares is also available. This offering follows a shelf registration with the SEC that was effective on November 16, 2020.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) has announced a public offering of $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. The offering is contingent on market conditions and is governed by a previously filed shelf registration statement with the SEC. J.P. Morgan, SVB Leerink, and Piper Sandler are the lead managers for the offering. This fundraising aims to support RAPT's development of oral therapies targeting significant unmet needs in oncology and inflammatory diseases.
RAPT Therapeutics announced positive topline results from its Phase 1b trial of RPT193 for moderate-to-severe atopic dermatitis. After four weeks, patients showed a 36.3% improvement in the Eczema Area and Severity Index (EASI) compared to 17.0% in the placebo group. Notably, a 53.2% improvement was recorded six weeks post-treatment. RPT193 was well tolerated with no serious adverse events. RAPT plans to advance RPT193 into a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma.
RAPT Therapeutics (Nasdaq: RAPT) announced it will release top-line results from its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis on June 14, 2021. This key data announcement signifies the company's ongoing commitment to addressing unmet medical needs in inflammatory diseases. The results will be shared during a conference call at 8:30 a.m. ET, which will be accessible via a live webcast. RAPT is developing targeted oral therapies focusing on CCR4, with RPT193 as a notable candidate in its pipeline.